MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Oragenics ROA Ratio 2011-2026 | OGEN
Annual ROA Ratio Oragenics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -97.76 | -717.68 | -415.92 | -96.82 | -55.65 | -141.49 | -78.8 | -44.96 | -93.3 | -162.75 | -202.68 | -52.01 | -95.47 | -124.81 | -606.09 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -44.96 | -717.68 | -199.08 |
Quarterly ROA Ratio Oragenics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -234.95 | -258.14 | -237.02 | -201.74 | -227.23 | -205.38 | -156.35 | -84.98 | -110.71 | -110.96 | -94.35 | -65.85 | -79.95 | -68.32 | -59.7 | -38.89 | -62.5 | -72.47 | -127.69 | -141.49 | -136.1 | -131.45 | -89.74 | -78.8 | -73.09 | -66.17 | -52.19 | -44.96 | -52.71 | -68.86 | -75.43 | -93.3 | -135.13 | -152.03 | -142.36 | -162.75 | -139.09 | -125.79 | -228.17 | -202.68 | -175.26 | -152.25 | -59.64 | -52.01 | -59.31 | -105.47 | -100.76 | -95.47 | -96.14 | -65.1 | -118.84 | -93.98 | -228.09 | -346.36 | -467.62 | -606.09 | -142.65 | -187.32 | -123.05 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -38.89 | -606.09 | -138.39 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M |  USA |
 |
Veracyte
VCYT
|
4.72 | $ 30.92 | -5.73 % | $ 2.43 B | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-206.44 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-78.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-437.72 | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-62.67 | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-34.23 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-41.82 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-11.6 | $ 12.67 | -9.24 % | $ 1.92 B | USA |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 321.51 | -2.03 % | $ 42.1 B | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-94.17 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-30.95 | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-54.23 | $ 1.09 | - | $ 22.4 M | Israel |
 |
Enochian Biosciences
ENOB
|
-2162.69 | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
-70.24 | $ 1.91 | -7.28 % | $ 109 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 19.46 | -0.36 % | $ 910 M | USA |
 |
Amarin Corporation plc
AMRN
|
-5.78 | $ 14.23 | -2.97 % | $ 5.91 B |  Irlanda |
 |
Bellerophon Therapeutics
BLPH
|
-249.92 | - | -74.18 % | $ 955 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 45.99 | -3.28 % | $ 4.14 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
-35.41 | $ 4.33 | -2.81 % | $ 830 M | Canada |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
-49.15 | - | -5.38 % | $ 6.06 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-102.69 | - | - | $ 384 M | Britain |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |